Skip to content

Inspection Record

Nanovis LLC — FDA 483 Findings

US FDAInspected 2026-03-19Published 2026-11-12 6 findingsOther quality systemValidation and qualificationEquipment and facilityProcess validation

Inspectors Suyang Qin · Shawn ChoiThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Changes necessary to ensure and maintain the continued suitability, adequacy, and effectiveness of the quality management system and medical device safety and performance were not adequately identified and implemented.

2Validation and qualification

Procedures for validation of processes did not adequately include statistical techniques with rationale for sample sizes and use of specific methods, procedures, and acceptance criteria.

3Equipment and facility

Purchasing information does not adequately describe or reference the product to be purchased, including requirements for product acceptance, procedures, processes, and equipment.

4Other quality system

Requirements for the work environment, and the procedures to monitor and control the work environment, were not adequately documented where conditions for the work environment can have an adverse effect on product quality.

5Other quality system

Changes to quality management system processes were not adequately controlled in accordance with requirements and evaluated for their impact on the quality management system and the medical devices produced.

6Process validation

Production controls do not include implementation of monitoring and measurement of process parameters and product characteristics.

A record as of the US FDA document published on 2026-11-12. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Nanovis LLC company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.